The Trader Harbor
  • Business
  • Politics
  • World News
  • Stocks
  • Business
  • Politics
  • World News
  • Stocks

The Trader Harbor

World News

FDA officially authorizes Zyn nicotine pouches for sale following health review

by admin January 18, 2025
January 18, 2025
FDA officially authorizes Zyn nicotine pouches for sale following health review

The U.S. Food and Drug Administration formally authorized Zyn nicotine pouches for sale after conducting an ‘extensive scientific review’ about their safety.

In a release Thursday, the agency said it had found that the popular pouches posed lower risk of cancer and other serious health conditions compared with cigarettes, as well as in relation to other smokeless tobacco products.

The agency also found that the pouches even had the potential to benefit cigarette smokers amid evidence that they can get them to quit.

‘The data show that these nicotine pouch products meet that bar by benefiting adults who use cigarettes and/or smokeless tobacco products and completely switch to these products,” Matthew Farrelly, director of the office of science in the FDA’s Center for Tobacco Products, said in a statement. 

Zyn use has exploded in recent years in the wake of a viral online meme trend, even prompting a shortage last year. Yet the product had been operating in a legal gray area while it underwent official FDA review about its health effects and uptake among young users.

To that latter point, the FDA found that, so far, Zyn use among youths appeared to be relatively low, though it was continuing to monitor the trend.

A spokesperson for Philip Morris International Inc., which owns the U.S. rights to Zyn, did not immediately respond to a request for comment.

Swedish Match, the developer of Zyn, said in a statement, “The FDA’s authorization of all ZYN nicotine pouches currently marketed by Swedish Match in the U.S. is an important step to protect the public health by providing better alternatives to cigarettes and other traditional tobacco products for adults 21+.”

The Campaign for Tobacco-Free Kids slammed the FDA’s decision in a separate statement.

‘The FDA today has set a dangerous precedent that puts the nation’s kids at risk by authorizing the sale of 20 Zyn nicotine pouch products with flavors that clearly appeal to kids, including chill, citrus, cool mint and peppermint,’ it said.

‘The FDA’s decision is deeply troubling given the extensive scientific evidence that flavored tobacco products appeal to kids and the fact that nicotine pouches were the only category of tobacco product that saw an increase in youth use last year. The FDA is sanctioning a flavored tobacco product that is already increasing in popularity with kids and repeating the mistakes it made with Juul that resulted in the youth e-cigarette epidemic.’

In the release, the FDA emphasized that its findings about Zyn did not mean the products are ultimately safe or “FDA approved.”

‘There is no safe tobacco product,’ the agency said. ‘Youth should not use tobacco products and adults who do not use tobacco products should not start.’

This post appeared first on NBC NEWS

0
FacebookTwitterGoogle +Pinterest
previous post
Capital One outage drags into Friday afternoon, leaving some customers without deposit access
next post
Vanguard fined more than $100 million by SEC over violations involving target date retirement funds

Related Posts

In federal trial, Michael Kors says it’s harder...

September 18, 2024

Protesters stage sit-in outside New York Stock Exchange...

October 16, 2024

Tesla’s law firm drafts Delaware bill that could...

February 19, 2025

Charter rolls out new Spectrum pricing and internet...

September 18, 2024

Nvidia’s CEO did a Q&A with analysts. What...

March 28, 2025

How investors can prepare for lower interest rates:...

August 25, 2024

Dow tumbles 475 points, S&P 500 suffers worst...

April 17, 2024

Here’s why business leaders are spending big on...

December 26, 2024

Apple boosts U.S. investment plans with $500 billion...

February 25, 2025

How ESPN executives plan to survive the decline...

March 25, 2024

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest

    • Larry Williams on the Fed, Interest Rates & Markets! What’s Next?

      June 2, 2025
    • Breakouts, Momentum & Moving Averages: 10 Must-See Stock Charts Right Now

      June 2, 2025
    • Senate Republicans eye changes to Trump’s megabill after House win

      June 2, 2025
    • Trump shares post saying Biden was executed, replaced with clones

      June 2, 2025
    • House Dems’ campaign chair says her party’s ‘on offense’ in 2026 battle to win back majority from GOP

      June 2, 2025
    • Kevin Hassett ‘very, very confident’ courts will back Trump’s tariffs amid legal setback

      June 2, 2025

    Categories

    • Business (1,220)
    • Politics (3,611)
    • Stocks (1,379)
    • Uncategorized (45)
    • World News (1,213)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: TheTraderHarbor, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 thetraderharbor.com | All Rights Reserved